Download Image
    
Share
  
Post
Selinexor for COVID-19
1 study with 117 patients
Hospital Icon Control
Hospital Icon Selinexor Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Selinexor studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -286% Mortality -286% Viral clearance 21% RCTs -286% Late -286% Favorsselinexor Favorscontrol
Selinexor is an oral small molecule Selective Inhibitor of Nuclear Export (SINE) that blocks the transport protein exportin-1 (XPO1). By inhibiting XPO1, selinexor prevents the nuclear export of viral ribonucleoproteins and restores the nuclear localization of host anti-inflammatory and tumor suppressor proteins, theoretically reducing viral replication and mitigating cytokine storm. Recent:
Geils.
Oct 10
2020
 Geils et al., Karyopharm Therapeutics Treatment of Severe COVID-19 with Low-Dose Selinexor: Demonstration of Anti-Viral and Anti-Inflammatory Activities in a Randomized, International, Multicenter, Placebo-Controlled Phase 2 Clinical Trial
286% higher mortality (p=0.07), 39% higher ventilation (p=0.58), 11% higher ICU admission (p=0.71), and 16% lower hospital discharge (p=0.68). RCT 188 hospitalized patients with severe COVID-19 showing higher mortality (p=0.07) and no significant clinical improvement with oral selinexor (20mg) compared to placebo. In the intention-to-treat analysis, the study failed its primary ..